{"preliminary_commentary":{"by_channel":{"x_thread":14,"x_video":3,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07218380\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["vepugratinib","enfortumab vedotin","pembrolizumab"]],"indication":null,"name":"FORAGER-2","nct_id":"NCT07218380","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=forager-2-nct07218380. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FORAGER-2","arms":[{"description":"Vepugratinib administered orally with EV + pembrolizumab administered IV","label":"Vepugratinib + EV + Pembrolizumab (Safety Lead In)","type":"EXPERIMENTAL"},{"description":"Vepugratinib administered orally, and EV + pembrolizumab administered by intravenous (IV) infusion.","label":"Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Placebo administered orally, and EV + pembrolizumab administered by IV infusion.","label":"Placebo + EV + Pembrolizumab","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2033-05","type":"ESTIMATED"},"conditions":["Carcinoma, Transitional Cell","Urinary Bladder Neoplasms","Neoplasm Metastasis"],"enrollment":{"count":450,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Vepugratinib","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"},{"name":"EV","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"Eli Lilly and Company","official_title":"FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab","timeFrame":"From baseline up to 90 months"},{"measure":"Safety Lead-in: Overall Response Rate (ORR)","timeFrame":"From baseline up to 90 months"},{"measure":"Progression-free Survival (PFS)","timeFrame":"Baseline to Study Completion (estimated as 6 years)"}],"references":[],"start_date":{"date":"2025-12-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","url":"https://clinicaltrials.gov/study/NCT07218380"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/forager-2-nct07218380"}